141 related articles for article (PubMed ID: 9616276)
1. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.
Paesmans M; Sculier JP; Libert P; Bureau G; Dabouis G; Thiriaux J; Michel J; Van Cutsem O; Sergysels R; Mommen P; Klastersky J
Eur J Cancer; 1997 Dec; 33(14):2326-32. PubMed ID: 9616276
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
Paesmans M; Sculier JP; Libert P; Bureau G; Dabouis G; Thiriaux J; Michel J; Van Cutsem O; Sergysels R; Mommen P
J Clin Oncol; 1995 May; 13(5):1221-30. PubMed ID: 7738625
[TBL] [Abstract][Full Text] [Related]
3. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party].
Sculier JP; Paesmans M; Libert P; Bureau G; Dabouis G; Thiriaux J; Michel J; Van Cutsem O; Schmerber J; Giner V; Berchier MC; Mommen P; Sergysels R; Klastersky J
Rev Mal Respir; 1997 Dec; 14(6):445-9. PubMed ID: 9496602
[TBL] [Abstract][Full Text] [Related]
5. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Libert P; Bureau G; Dabouis G; Thiriaux J; Michel J; Van Cutsem O; Schmerber J; Giner V
Eur J Cancer; 1994; 30A(9):1342-7. PubMed ID: 7999423
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
9. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
10. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.
Sculier JP; Paesmans M; Ninane V; Giner V; Bureau G; Lafitte JJ; Baumöhl J; Thiriaux J; van Cutsem O; Recloux P; Berchier MC; Zacharias C; Mommen P; van Houtte P; Klastersky J
Lung Cancer; 1998 Dec; 22(3):201-13. PubMed ID: 10048473
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years.
Paesmans M; Sculier JP; Lecomte J; Thiriaux J; Libert P; Sergysels R; Bureau G; Dabouis G; Van Cutsem O; Mommen P; Ninane V; Klastersky J
Cancer; 2000 Aug; 89(3):523-33. PubMed ID: 10931451
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
Borges M; Sculier JP; Paesmans M; Richez M; Bureau G; Dabouis G; Lecomte J; Michel J; Van Cutsem O; Schmerber J; Giner V; Berchier MC; Sergysels R; Mommen P; Klastersky J
Lung Cancer; 1996 Dec; 16(1):21-33. PubMed ID: 9017582
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Efremidis A; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
J Clin Oncol; 1998 Apr; 16(4):1388-96. PubMed ID: 9552042
[TBL] [Abstract][Full Text] [Related]
17. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
20. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
